Status:
COMPLETED
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Collins Medical Trust
Conditions:
CIDP
Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Detailed Description
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive disease leading to paralysis. CIDP is an immune-mediated disorder resulting from a synergistic interaction of T cell-mediated ...
Eligibility Criteria
Inclusion
- diagnosis of CIDP
- on a stable dose of immunotherapy for at least 3 months before enrolling in the study
Exclusion
- myelopathy or evidence of central demyelination
- persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
- evidence of systemic disease that might cause neuropathy
- heart diseases (congestive heart failure or arrhythmia)
- pulmonary conditions (asthma or CIPD)
- rheumatoid conditions (such as rheumatoid arthritis)
- renal failure
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00962429
Start Date
February 1 2009
End Date
January 1 2013
Last Update
August 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239